Navigation Links
Flow restrictors may reduce young children's accidental ingestion of liquid medications
Date:7/24/2013

ps were emptied. In contrast, none of the uncapped bottles with flow restrictors were emptied before 6 minutes, and only 6% of children were able to empty bottles with flow restrictors within the 10-minute test period. Overall, older children were more successful than younger children at removing liquid from the flow-resistant bottles. None of the youngest children (36-41 months) were able to remove 5 mL of test liquid, the amount in a standard dose of acetaminophen for a 2- to 3-year-old child.

Manufacturers voluntarily added flow restrictors to over-the-counter infant acetaminophen in 2011. Based on their effectiveness, the authors suggest that flow restrictors could be added to other liquid medications, especially those harmful in small doses. Importantly, according to study co-author Maribeth C. Lovegrove, MPH, "Flow restrictors are designed as a secondary barrier and caregivers should not rely on flow restrictors alone; adding flow restrictors could complement the safety provided by current child-resistant packaging." Caregiver education should continue to focus on consistently locking child-resistant caps and storing medications away and out of sight of children.


'/>"/>

Contact: Becky Lindeman
journal.pediatrics@cchmc.org
513-636-7140
Elsevier Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Soy-based S-equol supplement reduces metabolic syndrome risk factors
2. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
3. ONR taps research teams to help reduce jet noise
4. Nanocrystal-coated fibers might reduce wasted energy
5. Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations
6. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
7. Tax on salt could reduce cardiovascular disease deaths by 3 percent
8. How the ecological risks of extended bioenergy production can be reduced
9. Laparoscopy reduces the risk of small-bowel obstruction
10. Researchers show prebiotic can reduce severity of colitis
11. CUNY Energy Institute battery system could reduce buildings electric bills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... JUPITER, FL, October 26, 2010 The Scripps Research Institute ... Fox Foundation to study a pair of genetic mutations that ... for Parkinson,s disease, a progressive and fatal neurodegenerative disorder. ... director for drug discovery at Scripps Florida, is the principal ...
... the brain, which scavenge pathogens and damaged neurons, are also ... by Duke neuroscientists. Earlier studies by Staci Bilbo, an ... rats experiencing an infection at an early age have an ... learning and memory. In a study published in ...
... has a companion among emerging futuristic "e-sensing" devices intended ... is a "magnetic tongue" -- a method used to ... sweet, bitter, sour, etc. A report on use of ... Journal of Agricultural and Food Chemistry . ...
Cached Biology News:Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 2Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 3Source found for immune system effects on learning, memory 2Source found for immune system effects on learning, memory 3
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... CARLOS, Calif., Jan. 5 Nektar Therapeutics,(Nasdaq: ... Robin, is,scheduled to present at the upcoming 27th Annual ... St. Francis Hotel on Tuesday,January 13, 2009 at 10:00 ... The presentation will be accessible via ...
... ... (PRWEB) December 17, 2008 -- Facilitating the entry of ... analyzer, now updated to effortlessly examine not only the wireless interface ... but also the interface between the device CPU and the Bluetooth ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext ... identifies, develops and commercializes differentiated products for ... received clearance from Canadian regulatory authorities to ... for nimotuzumab, its EGFR-targeting antibody, in combination ...
Cached Biology Technology:Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7